Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bristol Tax Reporting (Correction)

This article was originally published in The Pink Sheet Daily

Executive Summary

Bristol-Myers Squibb's incoming tax reporting controls remain a "reportable condition," according to the company's auditors, PricewaterhouseCoopers.In a story on Bristol's latest earnings restatement, "The Pink Sheet" DAILY incorrectly reported that the tax controls are considered a "material weakness." Bristol has resolved both "material weaknesses" identified by PwC a year ago (1"The Pink Sheet" DAILY, March 15, 2004)

You may also be interested in...

Bristol Re-Restates; Income Taxes, "Grants" May Be Ongoing Issues

The company adjusts reported 2003 revenues by about $200 mil. Although impact of Bristol's second restatement is smaller than the first, tax issues and treatment of "grants" as advertising expenses could hint at deeper issues.

Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind

Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.

Bayer/J&J's Xarelto Approval For Stroke Prevention Sets Up Marketing Battle With Pradaxa

With an unrestricted label and once-daily dosing, rivaroxaban will do battle with Boehringer-Ingelheim's dabigatran, which is dosed twice a day but can claim superior efficacy to warfarin in the atrial fibrillation population.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts